免疫检查点抑制剂对罕见KRAS突变的晚期非小细胞肺癌患者的疗效：一项真实世界的回顾性研究

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2024-07-01 DOI:10.21037/tlcr-24-372

Haohua Jiang, Yujing Li, Yanan Wang, Benkun Zou, Ya Chen, Yanwei Zhang, Hatim Husain, Fabien Forest, F. Qian, Le-le Zhang, Chao Zhou, Hongyu Liu, Danni Wang, Wei Zhang, Jun Lu, Baohui Han

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.